td2 Archives

TGen-TD2-Scottsdale Healthcare study benefits patients


The Side-Out Foundation’s breast cancer pilot study, led by the Translational Genomics Research Institute (TGen), Translational Drug Development (TD2) and Scottsdale Healthcare, has shown that cancer patients do better when their treatment is guided by molecular profiling. Specifically, 52 percent of patients with advanced breast cancer received clinical benefit – meaning their disease was controlled… Read More →

FORMA Therapeutics Teams With TGen Drug Development

forma therapeutics

FORMA Therapeutics and TGen Drug Development (TD2) announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations. “TD2 brings preclinical and clinical development capabilities to FORMA, filling the missing piece in our strategy to become a fully-integrated research and development organization, leading the creation of breakthrough medicines for cancer… Read More →